This press release contains forward-looking statements about the potential of the investigational compound LY2062430 and reflects Lilly's current beliefs. However, as with any pharmaceutical product under development, there are substantial risks and uncertainties in the process of development and regulatory review. There is no guarantee that the product will receive regulatory approvals, or that the regulatory approval will be for the indication(s) anticipated by the company. There is also no guarantee that the product will prove to be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's filing with the United States Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.
(1) Small, GW, Rabins, PV, Barry, PP, Buckholtz, NS, DeKosky, ST, Ferris, SH, Finkel, SI, Gwyther, LP, Khachaturian, ZS, Lebowitz, BD, McRae, TD, Morris, JC, Oakley, F, Schneider, LS, Streim, JE, Sunderland, T, Teri, LA, Tune LE. Diagnosis and Treatment of Alzheimer Disease and Related Disorders: Consensus Statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA 1997; 278: 1363-1371.
(2) Alzheimer's Association. "2008 Alzheimer's Disease Facts and Figures." Available at: http://www.alz.org/national/documents/report_alzfactsfigures2008.pdf . Accessed July 1, 2008.
(3) American Public Health Association. "Mind Your Memory & Alzheimer's Disease!" Available at: http://www.apha.org/membergroups/newsletters/sectionnewsletters/public_edu/ fal l07/alzheimer.htm . Accessed July 1, 2008.
(4) Centers for Disease Control and Prevention. "National Vital
|SOURCE Eli Lilly and Company|
Copyright©2008 PR Newswire.
All rights reserved